Front. Immunol., 22 February 2022 | https://doi.org/10.3389/fimmu.2022.788619 Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges Samir K. Lakhashe1‡, Mario Amacker2,3‡, Dinesh Hariraju1,4,5‡, Hemant K. Vyas1, Kyle S. Morrison6, Joshua A. Weiner7, Margaret E. Ackerman6,7, Vicky Roy8, Galit Alter8,9, Guido Ferrari10,11, David C. Montefiori10,11, Georgia D. Tomaras10,11,12,13, Sheetal Sawant10, Nicole L. Yates10, Chris Gast14†, Sylvain Fleury3 and Ruth M. Ruprecht1,4,5* 1Texas Biomedical Research Institute, San Antonio, TX, United States 2Department of Pulmonary Medicine, Bern University Hospital, University of Bern, Bern, Switzerland 3Mymetics SA, Epalinges, Switzerland 4New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States 5Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States 6Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States 7Thayer School of Engineering, Dartmouth College, Hanover, NH, United States 8Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States 9Massachusetts Consortium on Pathogen Readiness, Boston, MA, United States 10Department of Surgery, Duke University, Durham, NC, United States 11Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States 12Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, United States 13Department of Immunology, Duke University, Durham, NC, United States 14Fred Hutchinson Cancer Research Center, Seattle, WA, United States Front. Immunol., 22 February 2022 | https://doi.org/10.3389/fimmu.2022.788619 Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges Samir K. Lakhashe1‡, Mario Amacker2,3‡, Dinesh Hariraju1,4,5‡, Hemant K. Vyas1, Kyle S. Morrison6, Joshua A. Weiner7, Margaret E. Ackerman6,7, Vicky Roy8, Galit Alter8,9, Guido Ferrari10,11, David C. Montefiori10,11, Georgia D. Tomaras10,11,12,13, Sheetal Sawant10, Nicole L. Yates10, Chris Gast14†, Sylvain Fleury3 and Ruth M. Ruprecht1,4,5* 1Texas Biomedical Research Institute, San Antonio, TX, United States 2Department of Pulmonary Medicine, Bern University Hospital, University of Bern, Bern, Switzerland 3Mymetics SA, Epalinges, Switzerland 4New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States 5Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States 6Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States 7Thayer School of Engineering, Dartmouth College, Hanover, NH, United States 8Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States 9Massachusetts Consortium on Pathogen Readiness, Boston, MA, United States 10Department of Surgery, Duke University, Durham, NC, United States 11Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States 12Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, United States 13Department of Immunology, Duke University, Durham, NC, United States 14Fred Hutchinson Cancer Research Center, Seattle, WA, United States https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
Clinical Trial Vaccine . 2003 Oct 1;21(27-30):4328-34. doi: 10.1016/s0264-410x(03)00457-2. Mucosal antibody response induced with a nasal virosome-based influenza vaccine P Durrer 1, U Glück, C Spyr, A B Lang, R Zurbriggen, C Herzog, R Glück
Market Data 
Markets 
AI
